Ketamine One (NEO:MEDI.AQN) Capital Ltd., which acquires clinics and other businesses that work across the mental health value chain, revealed that it has been engaged by Dr Tami Meraglia to establish a ketamine infusion clinic in Seattle, Washington.
The Vancouver, British Columbia-based company, which is consolidating healthcare clinics across North America, said the new clinic will operate as Seattle Ketamine Infusions (SKI) and be located at 311 West Republican Street in Seattle.
According to the company, Dr Meraglia is focused on the areas of personalized intravenous (IV) treatments and is also a national best-selling author. Dr Meraglia is also tapped by the media as a commentator on total health and wellness topics.
READ: Ketamine One in partnership to launch depression and PTSD clinical studies
Ketamine One (NEO:MEDI.AQN) will provide training, protocol development, and ongoing support for the clinic, with the “first patient treatments expected at SKI in early 2022”, said the company.
“Helping Dr Tami set up and open a ketamine clinic in the Seattle market is an exciting project for Ketamine One. We are looking forward to sharing our expertise and support, while also gaining from Dr Tami’s ability to engage with a large national audience,” Ketamine One interim CEO Adam Deffett said in a statement.
“Ketamine One continues to move closer to achieving its goal of becoming a leader in the mental health space across North America. By establishing great relationships with medical experts in new markets, such as Seattle, our ability to transfer knowledge is increasing and that is all for the benefit of patients,” he added.
Founded in 1997, KetamineOne’s subsidiary KGK Science is a top North American CRO based in London, Ontario that primarily provides clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive